Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

LENZ Therapeutics (LENZ) EBITDA Margin (2025)

LENZ Therapeutics (LENZ) has disclosed EBITDA Margin for 1 consecutive years, with 2259.51% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 2259.51% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 430.01% through Dec 2025, changed N/A year-over-year, with the annual reading at 430.01% for FY2025, N/A changed from the prior year.
  • EBITDA Margin for Q4 2025 was 2259.51% at LENZ Therapeutics, down from 132.09% in the prior quarter.
  • The five-year high for EBITDA Margin was 132.09% in Q3 2025, with the low at 2259.51% in Q4 2025.